Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread Formerly Known as No Rest For The Wicked -- Ignore unavailable to you. Want to Upgrade?

To: HandsOn who wrote (181)	11/15/1998 3:08:00 PM
From: Panita	Respond to of 90042

EGGS CEO performance on Monday's CNBC Squawk BOX...... If EGGS CEO can stand up to Mark "The BullDog" Haines barks, look for a good Monday morning for online auctioners: EBAY, ONSL, MALL, and EGGS. David Alger was positive on internet during his visit as guest on Friday's PBS Wall Street Week.

To: HandsOn who wrote (181)	11/17/1998 1:43:00 AM
From: Michael Berkel	Read Replies (1) \| Respond to of 90042

Re: CTII..excerpt from Nov.23 Business Week article. "But other companies may already have found a quicker route to these marvels. Already, Baltimore-based Osiris Therapeutic Inc. has regenerated bone in animals using another type of stem cell. And in Lincoln, R.I., CutoTherapeutics Inc. plans to treat Parkinson's disease using a neural stem cell. "We're not talking about something 10 to 20 years away, like GERON," says CEO Richard M. Rose, MD. Says James D McCament, editor of Medical Technology Stock Letter, "CytoTherapeutics is much closer to the clinic and more significant from an investment standpoint." Copyright 1998 The McGraw-Hill Companies For the price of an option, one can buy an interesting story stock before the Street & The Herd have found out about this one, better than Geron. Wait for the pop...!? Michael B.